Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tim Therapeutics Inc.’s portfolio is in Biotechnology & Pharmaceuticals and has 2 pending office actions. The matters involve 2 distinct examiners and 2 distinct art units, indicating separate examination channels within the pending record. Counsel should evaluate each action on its own merits and coordinate responses only where the underlying therapeutic issues are genuinely aligned.
PIPIC, ALMA is the busiest examiner, with 1 pending matter. One other examiner and art unit are also involved in the pending record. The practical implication is a need for separate examiner-focused arguments, consistent technical terminology, and docket oversight that keeps both biotechnology and pharmaceutical matters moving.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIPIC, ALMA | 1 | 54.8% | +54.3% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | PIPIC, ALMA | 53d |
| 18279612 | Compositions and Methods For Reducing Immune Intolerance | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | PIPIC, ALMA | 1617 | §103 | Final Rejection | 53d | Pending | Jan 17, 2024 |
| 18279612 | Compositions and Methods For Reducing Immune Intolerance | KIM, YUNSOO | 1641 | §112Other | Non-Final OA | — | Pending | Aug 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTim Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alma Pipic has the most, with 1 of Tim Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
